Dexrazoxane to Protect Against Hemorrhagic STEMI

Model scores of the 29,894 trials active now.

Model score 26% for any early termination, 16% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 15% of the time (446 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2026-03-16. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: mrimyocardialinfarctionheartacute
  Phrases that lowered it: adulthistory orclinically significantecgtrial
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Responsible party: sponsor investigator (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Number of arms: 2 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 96.9% (raises risk) · Drug's FDA history
• Drug's FAERS reports with a death: 11.4% (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Blinding: double (raises risk) · Design
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Collaborators: 0 (raises risk) · Design
• Design: sequential (raises risk) · Design
• Drug's FAERS reports before start: 1866 (raises risk) · Drug's FDA history
• Maximum age: 79 (lowers risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• The STREAM Percutaneous Coronary Intervention Anticoagulant Sub-study NCT00882635 · started 2008 · scored riskier than 81% of active trials completed
• Bivalirudin Infusion for Ventricular Infarction Limitation NCT02565147 · started 2014 · scored riskier than 48% of active trials terminated
• Direct Oral Anticoagulants for Prevention of lEft ventRIcular Thrombus After Anterior Acute Myocardial InFarction - APERITIF NCT05077683 · started 2021 · scored riskier than 66% of active trials completed
• Early Mineralocorticoid Receptor Antagonist Treatment to Reduce Myocardial Infarct Size NCT01882179 · started 2013 · scored riskier than 89% of active trials completed
• Sitagliptin Plus Granulocyte-colony Stimulating Factor in Acute Myocardial Infarction NCT00650143 · started 2008 · scored riskier than 37% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.